Get the Stockscreener App
80.21
0.90%
-0.73
Pre-market:
79.12
-1.09
-1.36%
Edwards Lifesciences Corp stock is traded at $80.21, with a volume of 3.18M.
It is down -0.90% in the last 24 hours and up +2.37% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$80.94
Open:
$80.57
24h Volume:
3.18M
Relative Volume:
0.81
Market Cap:
$47.09B
Revenue:
$5.69B
Net Income/Loss:
$1.41B
P/E Ratio:
11.54
EPS:
6.95
Net Cash Flow:
$577.90M
1W Performance:
-1.39%
1M Performance:
+2.37%
6M Performance:
+14.05%
1Y Performance:
+20.06%
1-Day Range:
$79.53
$80.80
1-Week Range:
$79.53
$82.67
52-Week Range:
$64.00
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
80.21 | 47.52B | 5.69B | 1.41B | 577.90M | 6.95 |
|
ABT
Abbott Laboratories
|
132.20 | 231.38B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
108.14 | 158.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
393.11 | 149.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.99 | 119.16B | 34.20B | 4.69B | 5.30B | 3.63 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Is This the Dip to Buy in Edwards Lifesciences Corporation2025 Earnings Impact & Community Trade Idea Sharing - beatles.ru
Is Edwards Lifesciences Corporation in a bullish channel2025 Market WrapUp & Safe Entry Zone Identification - beatles.ru
Edwards acquires Vectorious for $497M - BioWorld MedTech
Edwards Lifesciences’ TAVR growth continues as global demand rises - Yahoo Finance
Edwards Lifesciences Corporation stock trendline breakdown2025 Winners & Losers & Capital Efficiency Focused Ideas - Newser
Edwards buys remaining stake of Vectorious Medical Technologies and its heart implant - MassDevice
Edwards Lifesciences Acquires Israeli Medtech Firm Vectorious Medical for $497m Valuation - AInvest
What Fibonacci levels say about Edwards Lifesciences Corporation reboundWeekly Profit Report & Long-Term Growth Portfolio Plans - Newser
Is Edwards Lifesciences Corporation meeting your algorithmic filter criteriaMarket Sentiment Review & Real-Time Volume Trigger Notifications - Newser
Is it time to cut losses on Edwards Lifesciences CorporationMarket Growth Report & Reliable Entry Point Trade Alerts - Newser
Published on: 2025-09-03 02:50:15 - Newser
Using AI based signals to follow Edwards Lifesciences CorporationJuly 2025 Highlights & Fast Moving Market Watchlists - Newser
How to read the order book for Edwards Lifesciences CorporationJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - Newser
Building trade automation scripts for Edwards Lifesciences CorporationWeekly Profit Recap & Weekly Breakout Watchlists - Newser
Can Edwards Lifesciences Corporation stock recover from recent declineTrade Entry Summary & Low Volatility Stock Suggestions - Newser
Healthcare Stocks to Watch: argenx, ICON, and Edwards Lifesciences with Long-Term Potential - AInvest
Leerink Partners Lifts Edwards Lifesciences (EW) Price Target Amid Buybacks Focus - Yahoo Finance
Edwards Lifesciences Stock: Is EW Outperforming the Healthcare Sector? - Yahoo Finance
Is Edwards Lifesciences Corporation stock ready for a breakout2025 Top Decliners & Short-Term Swing Trade Alerts - Newser
Published on: 2025-09-01 12:29:31 - Newser
Signal strength of Edwards Lifesciences Corporation stock in tech scannersJuly 2025 Levels & Real-Time Stock Entry Alerts - Newser
Should you wait for a breakout in Edwards Lifesciences CorporationRecession Risk & Risk Controlled Stock Alerts - Newser
Forecasting Edwards Lifesciences Corporation price range with options data2025 Investor Takeaways & Weekly Chart Analysis and Guides - Newser
How institutional ownership impacts Edwards Lifesciences Corporation stockJuly 2025 Drop Watch & Fast Moving Trade Plans - Newser
Analyzing net buyer seller activity in Edwards Lifesciences CorporationWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - Newser
Edwards Lifesciences Stock: Is EW Outperforming The Healthcare Sector? - Barchart.com
Edwards Lifesciences celebrates new ESC guidelines - BioWorld MedTech
Edwards Lifesciences Corporation stock daily chart insightsDip Buying & Safe Entry Zone Tips - Newser
Edwards TAVR Gets Expanded ESC Guidelines for Severe AS Patients - Stock Titan
Edwards praises new aortic valve repair guidelines, reports positive Evoque data - MassDevice
Published on: 2025-08-29 06:42:54 - Newser
DBS Bank Adjusts Price Target on Edwards Lifesciences to $81 From $78, Maintains Hold Rating - MarketScreener
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.21%
3.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):